ClinicalTrials.gg

Leukemia, Myelogenous, Chronic, BCR-ABL Positive clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 895 studies for Leukemia, Myelogenous, Chronic, BCR-ABL Positive across more than 10 countries. 107 are recruiting or about to start. 516 of them are mainly about Leukemia, Myelogenous, Chronic, BCR-ABL Positive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 3 narrower conditions too, such as Leukemia, Myeloid, Chronic-Phase: 1,317 studies, 127 open.

ClinicalTrials.gov finds 1,304 studies for Leukemia, Myelogenous, Chronic, BCR-ABL Positive. How that becomes 895 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and those it files under no condition that list Leukemia, Myelogenous, Chronic, BCR-ABL Positivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,304Found by its condition search · See all 1,304 hereIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −418Filed under a narrower condition, counted on its own pageLeukemia, Myeloid, Chronic-Phase 314 · Blast Crisis 96 · Leukemia, Myeloid, Accelerated Phase 8
  3. −1List Leukemia, Myelogenous, Chronic, BCR-ABL Positive as a condition, but the registry did not file them under itMost often written as “Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative” (1) and “Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive” (1). The registry filed them under other conditions only, most often Leukemia, Biphenotypic, Acute (1) and Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1).
  4. −6Match it another way3 name it in the title and 3 by a synonym or other text the search reads.
  5. 879Counted here and found by its search
  6. +16
    Counted here, but its search does not find themThe registry filed them under no condition; they name Leukemia, Myelogenous, Chronic, BCR-ABL Positive in their own words, such as “Chronic Myeloid Leukemia in Chronic Phase” (4), “Chronic Myeloid Leukemia in Remission” (2), and “Chronic Phase Ph+ Chronic Myeloid Leukemia” (1), which its search for Leukemia, Myelogenous, Chronic, BCR-ABL Positive does not match.
  7. 895The count on this page

Status

Completed
478
Terminated
142
Recruiting
77
Status unknown
75
Active, not recruiting
46
Withdrawn
35

Phase

Phase 2
408
Phase 1
232
Phase 3
86
Phase 4
31
Early Phase 1
6

Where

United States
517
France
103
Italy
93
Germany
90
Canada
66
United Kingdom
57

Who develops what

Add Leukemia, Myelogenous, Chronic, BCR-ABL Positive to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 6 with this as their studies’ main aim; 4 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Hansoh Pharmaceutical Group and Novartis here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Tyrosine Kinase InhibitorsRecent, repeated
Evidence
  • NCT07905183 · Enliven Therapeutics · Phase 3 · live · comparator · “TKI” · registered Oct 2026
  • NCT07489755 · Shenzhen TargetRx Co., Ltd. · Phase 3 · live · comparator · “TKI” · registered Mar 2026
—22 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Relcobatinib☆ Track1 live phase-3 study: NCT07905183Enliven Therapeutics
Embibatinib☆ Track1 live phase-3 study: NCT07885293Hansoh Pharmaceutical Group Company Limited
Meribatinib☆ Track1 live phase-3 study: NCT07489755Shenzhen TargetRx Co., Ltd.
asciminibApproved: US 2021 · EU 2022☆ Track2 live phase-3 studies: NCT04971226, NCT05456191Novartis

The 4 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 3 Sept 2027 est.asciminib · Novartis · Phase 2 main aimNCT04925479 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia — primary endpoint: Primary Pharmacokinetic (PK) parameter: AUClast · 46 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 25 open · Antimetabolites 6 open · Alkylating agents 6 open · Calcineurin inhibitors 2 open · mTOR inhibitors 1 open

Coming up

44studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 77 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 47 (61%) set no upper age limit and 19 (25%) stop at 75 or younger. 20 (26%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 7 (9%) take healthy volunteers.

Recruiting studies that take each age, of 77
AgeWomenMen
1017 (22%)17 (22%)
1873 (95%)74 (96%)
3071 (92%)72 (94%)
4070 (91%)71 (92%)
5070 (91%)71 (92%)
6568 (88%)69 (90%)
7562 (81%)63 (82%)
8555 (71%)55 (71%)

Across all 895 studies, recruiting or not: 35% stop at 75 or younger and 20% at 65; 29% take children; <1% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies take

Of 125 phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 73 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 158 mo41–95 · 56 studies——
Phase 1/269 mo56–94 · 26 studies——
Phase 273 mo42–121 · 125 studies44 mo33–69 · 25 studies75 mo50–130 · 100 studies
Phase 338 mo30–79 · 24 studies——
Interventional, no phase41 mo22–123 · 25 studies——
Observational53 mo39–103 · 67 studies—58 mo46–142 · 45 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 895. Browse all 895 → or search them.